Praxis Precision Medicines, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Large accelerated filer
State of Incorporation
DE
Business Address
99 HIGH STREET, 30TH FLOOR, BOSTON, MA, 02110
Mailing Address
99 HIGH STREET, 30TH FLOOR, BOSTON, MA, 02110
Phone
617-300-8460
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| 10-K Annual financial report | February 19, 2026 | View on SEC |
| 8-K Current report of material events | February 19, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 12, 2026 | View on SEC |
| 8-K/A Current report amendment | February 10, 2026 | View on SEC |
| 4 Insider stock transaction report | February 10, 2026 | View on SEC |
| 4 Insider stock transaction report | February 10, 2026 | View on SEC |
Annual Reports
10-K
February 19, 2026
- Recognized as a "large accelerated filer" and "well-known seasoned issuer" with strong governance and transparency.
- Achieved positive Phase 2 data for PRAX-113 in essential tremor and initiated a crucial Phase 3 study for its lead epilepsy candidate.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.